(NASDAQ: NRIX) Nurix Therapeutics's forecast annual revenue growth rate of 24.29% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Nurix Therapeutics's revenue in 2025 is $56,417,000.On average, 9 Wall Street analysts forecast NRIX's revenue for 2025 to be $4,526,412,158, with the lowest NRIX revenue forecast at $1,410,358,489, and the highest NRIX revenue forecast at $5,980,682,349. On average, 7 Wall Street analysts forecast NRIX's revenue for 2026 to be $6,292,485,929, with the lowest NRIX revenue forecast at $2,287,067,820, and the highest NRIX revenue forecast at $16,202,350,793.
In 2027, NRIX is forecast to generate $8,316,159,771 in revenue, with the lowest revenue forecast at $5,097,874,171 and the highest revenue forecast at $15,576,456,566.